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Background: The worldwide epidemic of diabetes and obesity has resulted in a rapid upsurge in the prevalence of
metabolic syndrome (MetS). MetS makes the individual liable to endothelial dysfunction which can initiate sexual
dysfunction (SD). This study assessed the association between MetS and SD among clinically diagnosed diabetic
subjects in Tema, Greater Accra Region of Ghana.
Method: Sexual functioning was assessed using Golombok Rust Inventory of Sexual Satisfaction in 300 consecutive
diabetic men visiting the diabetic clinic of Tema General Hospital between November, 2010 and March, 2011.
Anthropometric data including waist and hip circumference as well as blood pressure were measured. The levels of
fasting blood glucose and serum lipid profile were assessed. All the men had a steady heterosexual relationship for
at least 2 years before enrolment in the study.
Results: The response rate was 91.3% out of the 300 subjects recruited for the study. Those with SD were
significantly older and had diabetes for a longer period as compared to those without SD. The prevalence of MetS
as defined by the various criteria was 78.8%, 43.4% and 51.8% for WHO, NCEP ATP III and IDF respectively. Central
obesity (p = 0.0482) and raised blood pressure (p = 0.0309) are the significant MetS components when the studied
population was stratified according to sexual functioning. Generally, SD as well as its sub-scales correlate positively
with age, blood pressure, duration of diabetes and MetS score. Whereas TC and LDL-c correlated positively with
non-communication, TG correlates positively with avoidance and infrequency.
Conclusion: SD and its sub-scales have a direct relationship with duration of diabetes, blood pressure and MetS
score from this study. Central obesity and raised blood pressure seem to be the link between MetS and SD among
this clinically diagnosed diabetic subjects.Background
Reduced sexual function, defined as the inability to par-
ticipate in a sexual relationship as one would wish has
multifactorial causes with medical and psychological
complications of diabetes being implicated [1-3]. By
2025, approximately 380 and 322 million people have
been projected to develop diabetes and sexual dysfunc-
tion (SD) respectively [4]. Metabolic syndrome (MetS),
diabetes, cardiovascular disease (CVD), obesity and SD
were previously perceived as independent factors for* Correspondence: nafamidu@yahoo.com
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reproduction in any medium, provided the oraging men. However, emerging data gives an indication
of their interrelatedness via multiple mechanisms [5].
MetS and SD are conditions associated with aging and
account for reduced quality of life. In the face of a grow-
ing worldwide epidemic of obesity, diabetes is expected
to facilitate the progression of MetS and SD and thus
lead to a reduction in quality of life.
MetS is defined as a constellation of conditions in-
volving at least three out of five risk factors including
abdominal obesity, elevated blood pressure, elevated
fasting blood glucose, high triglyceride as well as low
HDL-cholesterol. The prevalence of MetS and SD
would vary depending on the defining criteria, age, gen-
etic make-up, diet, occupation, cultural background,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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population involved. Depending on the criteria used
among Ghanaians, the prevalence of MetS varies between
11.5 - 15.5% among psychiatric patients [6], 1.6 – 14.4%
among active sportsmen and women [7], 13 – 18% among
garage workers in the automobile industry [8] and 30.1%
among chronic kidney disease patients [9]. MetS affected
individuals are subjected to endothelial dysfunction and
autonomic hyperactivity which sets the stage for metabolic
risk factors inducing SD [10].
The prevalence of SD among the Ghanaian commu-
nity has been reported to vary between 59.8 to 70% de-
pending on the population [11,12], medical conditions
[13] and marital status [14]. Previous reports among
this same population of clinically diagnosed diabetic
subjects indicated an SD rate of 69.3% [15]. This rate
appears to be related to infrequency of the sexual act
(79.2%), non-sensuality (74.5%), dissatisfaction (71.9%),
lack of communication (70.8%) and impotence (67.9%).
Other areas of sexual function, including premature
ejaculation (56.6%) and avoidance (42.7%) were also
substantially affected [15].
Even though some studies support the existence of an
association between CVD and MetS which is a risk fac-
tor for endothelial dysfunction as well as vascular dam-
age, a link between SD and MetS also appear to exist.
However, the nature of the association using Golombok
Rust Inventory of Sexual Satisfactory as an assessment
of sexual function with MetS is limited among diabetic
subjects. These are interconnected conditions in terms
of their cause and require an integrated approach. This
study attempts to define the association between SD
and MetS among clinically diagnosed diabetic subjects
using Golombok Rust Inventory of Sexual Satisfactory.
To our knowledge, this is the first study seeking to de-
termine the association between MetS and SD among
this population in Ghana.Methods
Participants
This cross-sectional study was conducted among 300 clin-
ically diagnosed diabetic patients visiting Tema General
Hospital in the Greater Accra region of Ghana. Sexually
active individuals who are at least 18 years and engaged
in or maintained heterosexual relationship for at least
2 years regardless of their marital status were recruited
in a consecutive procedure from November 2010 to
March 2011. Participation of the respondents was vol-
untary and informed consent was obtained from each
participant. The study was approved by the Committee
on Human Research, Publication and Ethics of the
School of Medical Science and the Komfo Anokye
Teaching Hospital, Kumasi.Anthropometric data
Information on age and duration of diabetes were col-
lected using a semi-structured questionnaire. Waist cir-
cumference (to the nearest centimetre) was measured
with a Gulick II spring-loaded measuring tape (Gay Mill,
WI) midway between the inferior angle of the ribs and the
suprailiac crest. Hip circumference was measured as the
maximal circumference over the buttocks in centimetres
and the waist-to-hip ratio (WHR) calculated by dividing
the waist circumference (cm) by the hip circumference
(cm). Blood pressure was measured by qualified nurses
using a mercury sphygmomanometer and stethoscope.
Measurements were taken from the upper left arm after
subjects had been sitting for >5 minutes in accordance
with the recommendation of the American Heart Associ-
ation [16]. Duplicate measurements were taken with a
5 minutes rest interval between measurements and the
mean value was recorded to the nearest 2.0 mmHg.
Golombok rust inventory of sexual satisfaction (GRISS)
Sexual function was assessed using GRISS questionnaire.
The GRISS has 28 items on a single sheet and is used for
assessing the existence and severity of sexual problems in
heterosexual couples or individuals who have a current
heterosexual relationship. All the 28 questions are an-
swered on a five-point (Likert type) scale from “always”,
through “usually”, “sometimes”, and “hardly ever”, to
“never”. It provides overall scores of the quality of sexual
functioning within a relationship. In addition, subscale
scores of impotence, premature ejaculation, infrequency,
non-communication, dissatisfaction, non-sensuality and
avoidance can be obtained and represented as a profile.
Responses are summed up to give a total raw score (range
28–140). The total score and subscale scores are
transformed using a standard nine point scale, with high
scores indicating greater problems. Scores of five or more
are considered to indicate SD. The GRISS was chosen
because it is standardized, easy to administer and score,
relatively unobtrusive and substantially inexpensive. The
reliability of the overall scales has been found to be 0.94
for men, and that of the subscales on average 0.74 (ranging
between 0.61 and 0.83). Validity has been demonstrated
under a variety of circumstances [17-19].
Sample collection, preparation and analysis
After observing an overnight fast, 6 ml of venous blood
sample was collected from each participant in the morn-
ing between 07:00 to 09:00 GMT into fluoride oxalate and
evacuated gel tubes (Becton Dickinson, Rutherford, NJ).
Blood samples in the fluoride oxalate and evacuated gel
tubes were centrifuged at 500 g for 15 minutes within
30 minutes of sample collection and separated into plasma
and serum respectively. The plasma sample was used for
fasting blood glucose measurement using BT 3000W
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Serum derived from the evacuated gel tubes were stored
in cryovials at −80°C until time for lipid profile measure-
ment using BT 3000W Random Access Chemistry
Analyzer (Biotecnica, Italy). The methods adopted by the
automated instruments for the determination of biochem-
ical parameters were according to the reagent manufac-
turers’ instructions (JAS Diagnostics, Inc. Miami Florida,
USA and Abbott Diagnostics, USA).Metabolic syndrome definitions
National cholesterol education program, adult treatment
panel III (NCEP ATP III)
MetS was defined according to the criteria of the National
Cholesterol Education Program, Adult Treatment Panel
III (NCEP ATP III) to include individuals with three or
more of the following five components: (1) abdominal
obesity (waist circumference > 102 cm); (2) high TG ≥
1.7 mmol/L (150 mg/dl); (3) low HDL-C : < 0.9 mmol/L
(< 40 mg/dl); and (4) High BP (systolic BP ≥ 130 mm Hg
or diastolic BP ≥ 85 mm Hg or treatment of hypertension)
and (5) high fasting glucose ≥ 6.1 mmol/l [20].International Diabetes Federation (IDF)
According to the new definition by the International Dia-
betes Federation (IDF) [21], MetS can be diagnosed if cen-
tral obesity (waist measurement >90 cm) is accompanied
by any 2 of the following 4 factors: (1) TG levels of
1.7 mmol/L or greater, (2) an HDL cholesterol lower than
1.03 mmol/L, (3) a blood pressure (BP) of 130/85 mm Hg
or greater or treatment of previously diagnosed hyperten-
sion, and (4) a fasting blood glucose (FBG) of 5.6 mmol/L
or greater or previously diagnosed type 2 diabetes.World Health Organization (WHO)
WHO criteria [21] required presence of diabetes
mellitus, impaired glucose tolerance or insulin resistance
and any two of the following: (1) waist-to-hip ratio >0.90,
(2) blood pressure ≥140/90 mmHg or on medication, (3)
diabetes ≥6.1 mmol/L or on medication for diabetes, im-
paired glucose tolerance or insulin resistance, (4) triglycer-
ide ≥1.7 mmol/L and/or HDL-C <0.91 mmol/L.Statistical analysis
The data were presented as mean ± standard deviation or
percentages. Continuous data were analyzed using un-
paired t-tests whilst categorical variables were analyzed
using Fischer’s exact test. In all statistical tests, a value of
p < 0.05 was considered significant. All analyses were
performed using SigmaPlot for Windows, Version 11.0,
(Systat Software, Inc. Erkrath, Germany) www.systat.com.Results
This study indicated 91.3% response rate out of the 300
subjects that were recruited for the study. Twenty sub-
jects found the subject matter too sensitive and hence
refused to partake in the study and 6 of the respondents
returned incomplete data leaving 274 evaluable data. As
shown in Table 1, respondents with SD were signifi-
cantly older and had been diagnosed with diabetes for a
longer period compared to the respondents without SD.
The mean ages as well as the mean duration of diabetes
from this study were 59.9 ± 11.3 years and 6.8 ± 5.9 years
respectively. Those with SD also had significantly higher
level of mean SBP as compared to their counterparts
without SD. The mean ± standard deviation of the bio-
chemical parameters was not significantly different be-
tween those with and without SD, even though those
with SD had generally higher values (Table 1). The mean
raw score for SD and its sub-scales were significantly
higher among those with SD except for avoidance and
infrequency (Table 1).
The prevalence of MetS as defined by the various cri-
teria was 78.8%, 43.4% and 51.8% for WHO, NCEP ATP
III and IDF respectively. Even though the prevalence of
MetS was found to be higher among those with SD irre-
spective of the criteria used, the differences were not sig-
nificant (Table 2). About 80%, 40% and 60% of the studied
population had MetS score of 3 or more using WHO,
NCEP ATP III and IDF criteria respectively. Classification
according to sexual function indicated that those with SD
generally have lower rates of MetS score of 1 and 2 but
higher rates of MetS score of 3 or more notwithstanding
the fact that the differences were not significant (Table 2).
Using the WHO criteria, the highest prevalence of com-
ponents of MetS was central obesity as measured by
WHR (76.6%), followed by hypertension (59.5%) and
hyperlipidemia (47.8%). From the NCEP ATP III criteria,
the highest prevalence of components of MetS was raised
BP (73.0%) followed by raised TG (32.1%), reduced HDL-
C(i.e. 28.5%) and abdominal obesity as measured by WC
(19.3%). Raised BP had the highest prevalence rate
(73.0%), followed by abdominal obesity (65.0%), raised TG
(32.1%) and reduced HDL-C (28.5%) using the IDF criteria
(Table 3). When the studied population was classified
according to sexual functioning, those with SD signifi-
cantly (p = 0.0482) had higher rates of central obesity
(80.0%) as compared to those without SD (69.9%) using
WHO criteria. However, when the NCEP ATP III and IDF
criteria were applied, the prevalence rate of MetS among
individuals with raised BP was significantly (p = 0.0309)
higher among those with SD (76.8%) as compared to those
without SD (64.3%) as shown in Table 3.
Generally, SD as well as its sub-scales correlated posi-
tively with age, blood pressure and duration of diabetes.
Whereas TC and LDL-c correlated positively with non-
Table 1 General characteristic of the study population stratified by sexual dysfunction
Variables Total (n = 274) NSD (n = 84) SD (n = 190) P value
Socio-demographic data
Age (years) 59.9 ± 11.3 56.2 ± 11.6 65.1 ± 7.5 <0.0001
Duration of diabetes (years) 6.8 ± 5.9 6.0 ± 5.6 8.5 ± 6.2 0.0012
Anthropometric data
SBP (mmHg) 151.5 ± 24.7 148.8 ± 25.7 157.6 ± 21.1 0.0063
DBP (mmHg) 96.2 ± 17.7 94.8 ± 16.9 99.4 ± 19.1 0.0504
Hip circumference (cm) 100.7 ± 9.5 100.0 ± 7.6 101.0 ± 10.3 0.4559
Waist circumference (cm) 94.5 ± 16.0 94.6 ± 16.3 94.4 ± 15.9 0.9025
WHR 0.9 ± 0.2 0.9 ± 0.2 0.9 ± 0.1 0.5362
Biochemical parameters
FBG (mmol L-1) 9.4 ± 4.0 9.3 ± 3.4 9.4 ± 4.2 0.8254
Total cholesterol (mmolL-1) 5.2 ± 1.2 5.1 ± 1.1 5.3 ± 1.3 0.2021
Triglyceride (mmolL-1) 1.4 ± 0.7 1.4 ± 0.8 1.5 ± 0.7 0.3137
HDL-cholesterol (mmolL-1) 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 0.5161
LDL-cholesterol (mmolL-1) 3.3 ± 1.1 3.3 ± 1.0 3.5 ± 1.2 0.1279
Testosterone (ng mL-1) 6.3 ± 2.5 6.7 ± 2.8 6.0 ± 2.1 0.0250
Raw score for sexual dysfunction and its sub-scales
Sexual dysfunction 72.2 ± 10.6 58.8 ± 8.0 78.1 ± 4.4 <0.0001
Impotence 11.3 ± 2.1 9.2 ± 1.6 12.3 ± 1.6 <0.0001
Premature ejaculation 7.4 ± 2.9 4.8 ± 1.5 8.5 ± 2.6 <0.0001
Non-sensuality 11.6 ± 2.5 9.2 ± 2.2 12.7 ± 1.7 <0.0001
Avoidance 8.0 ± 3.2 7.8 ± 4.5 8.1 ± 2.5 0.5710
Dissatisfaction 11.3 ± 1.6 10.0 ± 1.7 11.8 ± 1.2 <0.0001
Non-communication 4.2 ± 1.5 3.0 ± 1.1 4.8 ± 1.3 <0.0001
Infrequency 5.3 ± 1.4 5.1 ± 1.4 5.4 ± 1.4 0.0796
Data are presented as mean ± s.d; P-value defines the level of significance when subjects with no sexual dysfunction (NSD) were compared to those with sexual
dysfunction (SD)(Unpaired t-test); SBP-systolic blood pressure; DBP-diastolic blood pressure; WHR-waist to hip ratio; FBG-fasting blood glucose; HDL-high density
lipoprotein; LDL-low density lipoprotein.
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and infrequency (Table 4). Sexual dysfunction, PE, NS,
AV, DIS and INF generally correlated positively with
MetS scores with small size effect irrespective of the cri-
teria used (Table 4).
Discussion
Even though the causal relationship is still unclear, avail-
able data supports an association between SD and MetS.
Thus, this study was conducted to define the association
between SD and MetS among men who have been clinic-
ally diagnosed with diabetes mellitus. The prevalence of
SD has been reported among these same clinically diag-
nosed diabetic men to be 69.3% [15]. This SD rate was
found to be related to infrequency (79.2%), non-sensuality
(74.5%), dissatisfaction with sexual acts (71.9%), non-
communication (70.8%) and impotence (67.9%). Other
areas of sexual function, including premature ejaculation
(56.6%) and avoidance (42.7%) were also substantiallyaffected [15]. SD was found to be associated with de-
creased testosterone levels and varied according to age
with obesity being one of the determinants [15].
Irrespective of the criteria used in the definition, MetS
does not represent a disease state in itself but a step to-
wards global dysfunction. From this study, ≈ 40% to 80%
of the diabetic men can be classified as having MetS de-
pending on the definitive criteria employed. Among those
with SD, the prevalence of MetS was 44.2%, 52.1% and
80.0% using the NCEP ATP III, IDF and WHO criteria re-
spectively. The prevalence of MetS observed in this study
is similar to the 90.1% observed among men with SD [22]
and the 96.5% of MetS subjects exhibiting SD [23]. The
lack of significant difference in the estimated prevalence of
MetS between those with and without SD from this study
could be due to the fact that all the subjects were diabetic
and are thus susceptible to the development of endothelial
dysfunction since both SD and MetS are thought to be
mediated by endothelial dysfunction.
Table 2 Prevalence of metabolic syndrome and metabolic score among the studied population stratified by sexual
function
Variable Total (n = 274) NSD (n = 84) SD (n = 190) P value
Prevalence of MetS
WHO 216(78.8%) 64(76.2%) 152(80.0%) 0.4766
NCEP ATP III 119(43.4%) 35(41.7%) 84(44.2%) 0.6953
IDF 142(51.8%) 43(51.2%) 99(52.1%) 0.8889
Prevalence of clustering of components of MetS
WHO
0 0(0.0%) 0(0.0%) 0(0.0%)
1 11(4.0%) 4(4.8%) 7(3.7%) 0.6752
2 46(16.8%) 16(19.0%) 30(15.8%) 0.5059
≥3 217(79.2%) 64(76.2%) 153(80.5%) 0.4149
NCEP ATP III
0 3(1.1%) 0(0.0%) 3(1.6%) 0.2469
1 46(16.8%) 13(15.5%) 33(17.4%) 0.6992
2 107(39.1%) 34(40.5%) 73(38.4%) 0.7478
≥3 118(43.1%) 32(38.1%) 86(45.3%) 0.2692
IDF
0 1(0.4%) 0(0.0%) 1(0.5%) 0.5053
1 20(7.2%) 8(9.5%) 12(6.3%) 0.3466
2 87(31.8%) 31(36.9%) 56(29.5%) 0.2231
≥3 166(60.6%) 49(58.3%) 117(61.6%) 0.6122
Data are presented as proportions; P value defines the level of significance when subjects with no sexual dysfunction (NSD) were compared to those with sexual
dysfunction (SD) (Fischer’s exact test).
Table 3 Prevalence of the various metabolic syndrome risk factors among the study population classified by sexual
function
Variable Total (n = 274) NSD (n = 84) SD (n = 190) P value
WHO
Central Obesity – WHR 210(76.6%) 58(69.0%) 152(80.0%) 0.0482
Raised fasting glucose 274(100.0%) 84(100.0%) 190(100.0%)
Hyperlipidaemia 131(47.8%) 36(42.9%) 95(50.0%) 0.2751
Raised blood pressure 163(59.5%) 47(56.0%) 116(61.1%) 0.4278
NCEP ATP III
Abdominal Obesity – WC 53(19.3%) 13(15.5%) 40(21.1%) 0.2813
Raised fasting glucose 274(100.0%) 84(100.0%) 190(100.0%)
Raised Triglyceride 88(32.1%) 25(29.8%) 63(33.2%) 0.5788
Raised blood pressure 200(73.0%) 54(64.3%) 146(76.8%) 0.0309
Reduced HDL-C 78(28.5%) 21(25.0%) 57(30.0%) 0.3978
IDF
Abdominal Obesity – WC 178(65.0%) 52(61.9%) 126(66.3%) 0.4804
Raised fasting glucose 274(100.0%) 84(100.0%) 190(100.0%)
Raised Triglyceride 88(32.1%) 25(29.8%) 63(33.2%) 0.5788
Raised blood pressure 200(73.0%) 54(64.3%) 146(76.8%) 0.0309
Reduced HDL-C 78(28.5%) 21(25.0%) 57(30.0%) 0.3978
Data are presented as proportion with corresponding percentages in parenthesis. The proportions were compared using Fischer’s exact test.
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Table 4 Partial correlations between sexual dysfunction parameters and determinants of metabolic syndrome
Variable SD IMP PE NS AV DIS NC INF
Age 0.39*** 0.31*** 0.33*** 0.39*** 0.15* 0.24*** 0.21*** −0.06
SBP 0.23*** 0.15* 0.27*** 0.23*** 0.02 0.22*** 0.08 0.05
DBP 0.19** 0.15* 0.21*** 0.17** −0.01 0.24*** 0.06 0.09
DOD 0.26*** 0.11 0.27*** 0.20*** 0.00 0.27*** 0.09 0.05
WC 0.04 0.11 −0.04 −0.10 −0.03 −0.09 −0.08 −0.05
WHR 0.01 0.08 −0.05 0.03 0.10 0.03 0.13* 0.02
FBG 0.06 0.05 0.04 0.04 0.16** −0.07 0.00 0.09
TC 0.05 0.05 −0.02 −0.04 0.01 −0.03 0.18** −0.04
TG 0.14 0.04 −0.09 −0.02 0.23*** −0.03 0.03 0.29***
HDL-c 0.05 0.11 0.03 0.06 0.00 0.03 0.03 0.02
LDL-c 0.06 0.00 −0.02 −0.09 0.10 −0.04 0.18** 0.01
WHO 0.16** 0.08 0.17** 0.16** 0.10 0.15* 0.00 0.15*
ATP 0.16** 0.01 0.13* 0.12* 0.14* 0.11 0.08 0.19**
IDF 0.21*** 0.08 0.17** 0.22*** 0.14* 0.16** 0.06 0.16**
*Correlation is significant at the 0.05 level (2-tailed), **Correlation is significant at the 0.01 level (2-tailed), ***Correlation is significant at the 0.001 level (2-tailed).
Boldface r = Pearson product moment correlation coefficient with a medium size (0.30 ≤ r ≥ 0.50) effect. SBP-systolic blood pressure, DBP-diastolic blood pressure,
DOD-duration of diabetes, WC-waist circumference, WHR-waist to hip ratio, TC-total cholesterol, TG-triglycerides, HDL-c-high density lipoprotein-cholesterol,
LDL-c-low density lipoprotein-cholesterol, SD-sexual dysfunction, IMP-impotence, PE-premature ejaculation, NS-non-sensuality, AV-avoidance, DIS-dissatisfaction,
NC-non-communication, INF-infrequency.
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sub-scales with MetS scores lends credence to the asso-
ciation between MetS and SD. MetS could lead to SD
through various processes. MetS is associated with de-
creased testosterone level and can lead to SD through
endothelial dysfunction which has been linked with vas-
cular disorders or change in testosterone:estrogen levels
[24] or through atherosclerosis which can cause struc-
tural damage within the penile tissues [25].
Among these diabetic subjects, a positive correlation
existed between SD, premature ejaculation, non-sensuality
and dissatisfaction with duration of diabetes. In diabetic
subjects, there is on-going cellular activity leading to in-
creased production of reactive oxygen species (e.g. su-
peroxide anion) that deactivates nitric oxide [26,27].
Increased endothelial dysfunction among diabetic subjects
also leads to reduction in vascular nitric oxide, impaired
vasodilation, increased free radical production and athero-
sclerotic damage [28]. Long-standing diabetes can also
lead to glycation of penile cavernosal tissue [29] and uro-
genital sensory neuropathy [30].
MetS, diabetes, CVD including hypertension, obesity
and SD were previously thought to be independent factors
for aging men. However, MetS and SD have received a
great deal of attention over the past decades due to their
association with CVD and diabetes in the face of a grow-
ing worldwide epidemic of obesity. The complex relation-
ship between MetS and SD among these diabetic subjects
could be explained by the prevailing central obesity and
raised blood pressure. Obesity is not only a major compo-
nent of MetS, but also a key factor for MetS progression.Increased central obesity normally leads to increased lep-
tin that could be responsible for the decrease in testoster-
one level previously reported among this population [15]
via functional leptin receptor isoform on Leydig cells [31].
Enhanced aromatase activity also irreversibly catalyses the
conversion of testosterone to oestradiol due to the central
obesity of MetS leading to further visceral adiposity, in-
creased aromatase function and a positive feedback loop
(i.e. hypogonadal-obesity cycle) [32,33].
The mediating effect of raised blood pressure between
MetS and SD is in conformity with previous studies
[34,35]. Increased sympathetic tone in raised blood pres-
sure combined with endothelial dysfunction in MetS, or
other organic status, are the most plausible pathway for
inducing SD. The role of lipid profile including TC,
LDL-c and TG cannot be ignored due to their positive
correlation with non-communication, avoidance and in-
frequency which are key determinants of sexual func-
tioning in an individual. In MetS subjects, increased
production of cholesterol, LDL-c and TG can lead to de-
struction of endogenous nitric oxide synthetase [36,37],
decreased bioavailability of NO, increase in vasocon-
strictor factors and hence damaged endothelium-based
vasodilatation at the early stages of atherosclerosis
[38,39]. Further scientific enquiry is required for the es-
tablishment of a reciprocal cause between MetS and SD
among diabetic male patients.
Conclusion
The prevalence of MetS as defined by the various cri-
teria was 78.8%, 43.4% and 51.8% for WHO, NCEP ATP
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subjects with SD was 80.0%, 44.2% and 52.1% using
WHO, NCEP ATP III and IDF criteria respectively. There
was a strong positive correlation of SD and its sub-scales
with MetS scores, blood pressure, and the duration of dia-
betes which implies the worsening of SD once a subject
had MetS. Central obesity and raised blood pressure are
the link between MetS and SD among this cohort of dia-
betic patients.
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